The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Official Title: A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
Study ID: NCT05399654
Brief Summary: INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
University of Southern California (USC), Los Angeles, California, United States
University of Colorado, Aurora, Colorado, United States
Sarah Cannon Research Institute (SCRI)- Denver, Denver, Colorado, United States
AdventHealth Cancer Institute, Orlando, Florida, United States
Sarah Cannon Research Institute (SCRI)- Florida Cancer Specialists and Research Institute, LLC, Orlando, Florida, United States
John Theurer Cancer Center, Hackensack, New Jersey, United States
Weill Cornell Medicine- NYU Clinical Cancer Center, New York, New York, United States
West Cancer Center & Research Institute, Germantown, Tennessee, United States
The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
NEXT Oncology, Irving, Texas, United States
NEXT Oncology- Virginia, Fairfax, Virginia, United States
Clinical Site, Nedlands, Western Australia, Australia